Please login to the form below

Not currently logged in
Email:
Password:

CytomX

This page shows the latest CytomX news and features for those working in and with pharma, biotech and healthcare.

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Amgen pledges $1.5bn for CytomX preclinical cancer drugs. Stellar valuations for immuno-oncology candidates continue. ... Shares in US clinical stage biopharmaceutical company CytomX leaped more than a third on the latest deal.

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    BMS has expanded its 2014 agreement with CytomX Therapeutics to access up to eight further targets in oncology and other fields, using CytomX’s Probody platform. ... 650. CytomX Therapeutics. BMS. Strategic collaboration. Probody platform to enhance

  • Deal Watch April 2016 Deal Watch April 2016

    CytomX leads. Argenx undertakes R&D until IND, AbbVie thereafter it option exercised. ... Zymeworks, like CytomX, have multiple Big Pharma partners including Merck &Co and Lilly.

  • Pharma deals during May 2014 Pharma deals during May 2014

    BMS also entered into a platform deal with CytomX for so-called “ Probodies,” monoclonal antibodies that are selectively activated within the cancer microenvironment.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    CytomX / BMS. Development and commercialisation licence. Selective monoclonal antibodies (“ Probodies”) for up to 4 oncology targets.

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    818. CytomX / Pfizer. Collaboration and exclusive licence to selected PDCs.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • CytomX appoints Rachel Humphrey chief medical officer CytomX appoints Rachel Humphrey chief medical officer

    CytomX appoints Rachel Humphrey chief medical officer. Former VP of Eli Lilly and AstraZeneca joins the company. ... She said: “ Since joining the CytomX board of directors in March, I have been able to see at first-hand the tremendous power of the

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    CytomX Therapeutics has boosted both its senior science and business teams following a major antibody deal with Pfizer. ... His new colleague Ray joined CytomX in 2011 and was instrumental in brokering the agreement with Pfizer.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics